These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 32898396)

  • 21. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML).
    Dunna NR; Rajappa S; Digumarti R; Vure S; Kagita S; Damineni S; Rao VR; Yadav SK; Ravuri RR; Satti V
    Asian Pac J Cancer Prev; 2010; 11(6):1811-6. PubMed ID: 21338238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients.
    Zhang Y; Wang F; Chen X; Liu W; Fang J; Wang M; Teng W; Cao P; Liu H
    Front Med; 2019 Apr; 13(2):229-237. PubMed ID: 29806051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
    Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NPM1 and FLT3 mutations in acute myeloid leukemia with normal karyotype: Indian perspective.
    Sazawal S; Singh N; Jain S; Chhikara S; Chaubey R; Bhattacharyya J; Saikia KK; Mahapatra M; Saxena R
    Indian J Pathol Microbiol; 2017; 60(3):355-359. PubMed ID: 28937371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myeloid leukemia in patients older than 75: prognostic impact of FLT3-ITD and NPM1 mutations.
    Hirsch P; Qassa G; Marzac C; Tang R; Perrot JY; Isnard F; Mohty M; Marie JP; Legrand O
    Leuk Lymphoma; 2015 Jan; 56(1):147-50. PubMed ID: 24724782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1749-1755. PubMed ID: 31244296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Coexisting mutations in NPM1-mutated elderly adults with acute myeloid leukemia].
    Qin W; Chao HY; Cai XH; Lu XZ; Liu J; Wu P; Chen MY
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3152-3157. PubMed ID: 31694106
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
    Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute Myeloid Leukaemia with Gene Mutation: A Correlation with Haematological and Immunophenotypic Characteristics and Our Experience in a Tertiary Care Cancer Center in South India.
    Khera R; Ahmed F; Mundada M; Nambaru L; Murthy SS; Devig S; Rajappa SJ; Mallavarapu KM; Santa A; Kumar P
    Turk Patoloji Derg; 2018; 34(2):171-174. PubMed ID: 28984348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
    Wang LH; Wang M; Zhou CL; Chen S; Zhang XW; Xing HY; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
    How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
    Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of FLT3 mutational status and sustained expression of NPM1 mutation in paired presentation, and relapse samples in a patient with acute myeloid leukemia.
    Radojkovic M; Tosic N; Colovic N; Ristic S; Pavlovic S; Colovic M
    Ann Clin Lab Sci; 2012; 42(2):186-90. PubMed ID: 22585616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.